Lytgobi (futibatinib) Patient Assistance Program
Don’t let the high cost of brand FGFR2 inhibitor disrupt your cholangiocarcinoma treatment. We help eligible patients access Lytgobi (futibatinib tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Lytgobi (futibatinib) is FDA-approved for treatment of adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. Selective irreversible FGFR1/2/3/4 inhibitor. Precision oncology therapy based on a molecular biomarker.
- Without assistance, Lytgobi costs commonly run approximately $22,000+ per month.
- Through AffordMyPrescriptions, qualifying patients can access Lytgobi for a flat $69.95 per month.
- Other FGFR inhibitors for cholangiocarcinoma: pemigatinib (Pemazyre — brand; FGFR2 fusion cholangiocarcinoma), infigratinib (Truseltiq — withdrawn from US market). IDH1-mutant cholangiocarcinoma: Tibsovo (ivosidenib). HER2-positive: Ziihera (zanidatamab). MSI-H/dMMR: pembrolizumab (Keytruda), Jemperli (dostarlimab). NTRK fusion: Vitrakvi (larotrectinib), Rozlytrek (entrectinib). BRAF V600E: dabrafenib + trametinib. First-line: gemcitabine + cisplatin ± durvalumab (Imfinzi). Comprehensive molecular testing (NGS) essential.
What is Lytgobi Prescription Assistance Program?
The Lytgobi Patient Assistance Program helps eligible patients access this FGFR inhibitor at little or no cost when meeting income, insurance, and clinical criteria. Free to apply but involves detailed applications, oncology coordination, FGFR2 biomarker documentation, and renewal.
At AffordMyPrescriptions, our Patient Advocates handle the entire Lytgobi PAP enrollment for a flat $69.95 per month — so you never face a gap in Lytgobi cholangiocarcinoma therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Lytgobi enrollment — so you never face a gap in your FGFR2-fusion cholangiocarcinoma treatment.
Pharmacy Price Comparison
- Without assistance, Lytgobi costs thousands per month at specialty pharmacies. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Gemcitabine/cisplatin (chemo) | ~$1,000/cycle | 1L standard chemo alt |
| Specialty pharmacy | ~$22,000/mo | Save substantially |
| Walgreens Specialty | ~$23,000/mo | Save substantially |
| CVS Specialty | ~$24,000/mo | Save substantially |
| 340B-eligible institution | ~$19,000/mo | Save substantially |
| Pemazyre (alt FGFR) | ~$20,000/mo | Alt FGFR2 inhibitor |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Lytgobi — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Lytgobi Prescription Program?
The Lytgobi Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. FGFR2 fusion testing is critical — comprehensive NGS molecular profiling of cholangiocarcinoma is essential. Multiple actionable molecular alterations in cholangiocarcinoma justify testing.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Lytgobi assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Lytgobi is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Lytgobi:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $22,000+ per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Lytgobi assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Lytgobi Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Lytgobi:
Lytgobi is a selective irreversible FGFR1/2/3/4 inhibitor for FGFR2 fusion-positive intrahepatic cholangiocarcinoma. The irreversible mechanism may improve durability of response vs reversible FGFR inhibitors. Precision oncology built on a validated biomarker.
How It Works:
Cholangiocarcinoma (bile duct cancer) is a challenging cancer with limited historical treatment options. Molecular profiling has identified actionable alterations in intrahepatic cholangiocarcinoma: FGFR2 fusions or rearrangements (~10–15%), IDH1 mutations (~15–20%), HER2 amplification, MSI-H/dMMR, NTRK fusions, BRAF V600E. Precision oncology has transformed molecularly-selected cholangiocarcinoma treatment. Futibatinib is a selective irreversible inhibitor of FGFR1/2/3/4 tyrosine kinases — it covalently binds the FGFR active site, and the irreversible mechanism may improve durability vs reversible FGFR inhibitors. Effective in FGFR2 fusion-positive intrahepatic cholangiocarcinoma including patients with acquired resistance mutations to prior FGFR inhibitors. Alternative FGFR inhibitor: pemigatinib (Pemazyre) — reversible mechanism.
Form and Use:
Lytgobi tablets 4 mg. 20 mg once daily on an empty stomach. Continue until disease progression or unacceptable toxicity. Requires FGFR2 fusion testing. Ophthalmology monitoring for retinal effects. Phosphorus monitoring (dose adjust for hyperphosphatemia).
Generic Availability:
No generic Lytgobi. Other FGFR inhibitors for cholangiocarcinoma: pemigatinib (Pemazyre — brand; FGFR2 fusion cholangiocarcinoma; reversible mechanism), infigratinib (Truseltiq — brand, withdrawn from US market). IDH1 mutation: Tibsovo (ivosidenib — brand). HER2 amplification: Ziihera (zanidatamab — bispecific HER2 brand), Enhertu (T-DXd — off-label). MSI-H/dMMR: pembrolizumab (Keytruda), Jemperli (dostarlimab). NTRK fusion: Vitrakvi (larotrectinib), Rozlytrek (entrectinib). BRAF V600E: dabrafenib + trametinib. First-line cholangiocarcinoma: gemcitabine + cisplatin ± durvalumab (Imfinzi). Comprehensive NGS testing is essential. Cholangiocarcinoma Foundation.
Warnings:
Hyperphosphatemia (very common — FGFR inhibitor class effect; monitor and manage with dietary phosphate restriction, phosphate binders, dose adjustments), retinal detachment and other retinal disorders (ophthalmology monitoring at baseline, periodically, and for any visual changes), nail toxicities (common — onycholysis, onychomadesis, paronychia), embryo-fetal toxicity (contraindicated in pregnancy), hepatotoxicity. Other: fatigue, dry mouth, stomatitis, dry skin, nausea, dysgeusia, decreased appetite, diarrhea, muscle spasms. Drug interactions: CYP3A4 substrate (avoid strong inhibitors/inducers), P-gp interactions. Oncology and ophthalmology follow-up.
FAQ (Frequently Asked Questions)
How much does Lytgobi cost without insurance?
$22,000+ per month at specialty pharmacies. Pemigatinib (Pemazyre — alternative FGFR2 inhibitor) is similarly priced. Patient Assistance Programs are essential.
How is Lytgobi different from Pemazyre (pemigatinib)?
Both are FGFR inhibitors for FGFR2 fusion-positive cholangiocarcinoma. Lytgobi (futibatinib) has a selective irreversible mechanism — may improve durability of response and be active against some acquired FGFR resistance mutations. Pemazyre (pemigatinib) is a reversible FGFR inhibitor — a first-line FGFR-targeted option historically. Both effective in molecularly-selected patients; sequential use is possible in some cases.
Do I need FGFR2 fusion testing?
Yes — Lytgobi is for FGFR2 fusion or rearrangement-positive cholangiocarcinoma. Comprehensive next-generation sequencing (NGS) of tumor tissue detects FGFR2 fusions plus other actionable alterations (IDH1, HER2, BRAF, MSI, NTRK). Molecular testing is essential for optimal cholangiocarcinoma treatment selection.
What about other molecular alterations in cholangiocarcinoma?
Comprehensive NGS may identify: IDH1 mutation (~15–20% of intrahepatic — Tibsovo/ivosidenib), HER2 amplification (Ziihera/zanidatamab, Enhertu off-label), MSI-H/dMMR (Keytruda, Jemperli), NTRK fusion (Vitrakvi, Rozlytrek), BRAF V600E (dabrafenib + trametinib). Molecular testing enables precision therapy — multiple actionable alterations are possible in intrahepatic cholangiocarcinoma.
What are Lytgobi side effects?
Hyperphosphatemia (very common — dietary and pharmacologic management), retinal disorders (ophthalmology monitoring), nail toxicities (onycholysis, paronychia), fatigue, dry mouth, stomatitis, dry skin, nausea, dysgeusia, decreased appetite, diarrhea, muscle spasms. Hepatotoxicity possible. Embryo-fetal toxicity — contraindicated in pregnancy.
Take Control of Your Medication Costs
Precision therapy for FGFR2-driven cholangiocarcinoma offers hope for a challenging cancer. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.